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Introduction. Primary cardiac sarcoma (PCS) has a poor prognosis compared to other sarcomas due to late presentation, challenging
resection, incidence of metastases, and limited eﬃcacy of systemic therapies. Methods. A medical record search engine was queried to
identify patients diagnosed with PCS from 1992 to 2017 at the University of Michigan. Results. Thirty-nine patients with PCS had a
median age of 41 years (range 2–77). Common histologies were angiosarcoma (AS, 14), high-grade undiﬀerentiated pleomorphic
sarcoma (UPS, 10), and leiomyosarcoma (LMS, 5). Sites of origin were left atrium (18), right atrium (16), and pericardium (5). AS was
the most common right-sided tumor; UPS was more common on the left. Eighteen patients presented with metastases involving lung
(10), bone (7), liver (5), and brain (4). Twenty-ﬁve patients underwent resection, achieving 3 R0 resections. Patients received a median
of 2 (1–6) systemic therapies. Median overall survival (OS) was 12.1 months (range 0–79). Median OS was 14.0 months and 8.2
months in patients who did or did not undergo resection, respectively (p � 0.018). Brain metastases occurred in 12 (31%) patients, 9
(75%) of whom had left heart tumors, at a median of 8.5 months (range 0–75) from diagnosis. Median OS was 5.6 months (range
0–30) after the diagnosis of brain metastases. Conclusions. PCS portends a poor prognosis, because of diﬃculty in obtaining complete
resection of sarcoma, advanced stage at diagnosis, and high risk of brain metastases. Providers should be aware of the increased risk of
brain metastases and consider brain imaging at diagnosis and follow-up.

1. Introduction
Primary cardiac tumors are rare, with an overall incidence of
0.001–0.02% [1]. Of these, 25% are malignant, most commonly sarcomas. Consequently, the management of patients
with primary cardiac sarcomas (PCSs) is extrapolated from
small case series of aﬄicted patients and larger series of
patients with sarcomas of diﬀerent sites of origin but similar
histologic subtypes. PCSs are distinct entities with many
unique features coincident with their site of origin. As tumors are deep, visceral, and involve a critical organ, disease
is often locally advanced impairing resection by the time
symptoms develop.

We present a case series of 39 patients with PCS in
attempt to characterize and better understand disease presentation, location, treatment modalities, and overall survival of patients with PCS. We highlight patterns of
metastatic disease, histologic subtypes, and the barriers to
improvements in overall survival of PCS patients.

2. Materials and Methods
2.1. Patient Identiﬁcation. The University of Michigan
Electronic Medical Record Search Engine (EMERSE) was
searched using the terms “cardiac sarcoma” and “heart” plus
“sarcoma” to identify patients with a diagnosis of primary
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cardiac sarcoma treated at our institution between 1992 and
2017. Patients with sarcomas originating within the pulmonary vasculature or great vessels were not included in this
analysis. Details regarding demographics, clinical presentation, pathologic features, treatment protocols, and
outcome were extracted from clinical records. All research
was approved by the University of Michigan Institutional
Review Board (HUM00068553).
2.2. Statistical Analysis. Descriptive statistics, such as median and range, were calculated for continuous variables,
and frequencies were presented for categorical variables. To
compare two categorical variables, a frequency table was
created and analyzed using the chi-squared test or Fisher’s
exact test. Overall survival (OS) was estimated by the
Kaplan–Meier method and compared using the log-rank
test. Statistical signiﬁcance was deﬁned as a two-sided p
value <0.05. All analyses were conducted using SAS (version
9.4, SAS Institute, Cary, NC).

3. Results
3.1.
Demographics
and
Disease
Characteristics.
Thirty-nine patients with PCS presenting to the University of
Michigan between 1992 and 2017 were identiﬁed. Median
age at diagnosis was 41 years. Patient demographics and brief
outline of disease characteristics are summarized in Table 1.
The most common site of origin was the left heart.
All patients were symptomatic at time of diagnosis, most
frequently with dyspnea (n � 29), chest pain (n � 8), cough
(n � 3), bilateral lower extremity edema (n � 3), and hemoptysis (n � 3). Twenty patients had evidence of pericardial eﬀusion at diagnosis, including all 5 patients with
pericardial tumors and 11/16 patients with right-sided tumors. Twelve patients had evidence of tamponade at diagnosis, one of which had a left atrium (LA) tumor, 8 had
right atrium (RA) tumors, and 3 had pericardial tumors.
Eight patients had pulmonary hypertension at time of diagnosis. There were no clinically signiﬁcant arrhythmias
present at diagnosis.
Angiosarcoma was the most common tumor histology
and was more commonly located on the right side of the
heart (n � 11) and pericardium (n � 2, p < 0.0001) compared to other histologies. UPS (n � 8) and LMS (n � 4)
were the most commonly observed left-sided tumors
(Figure 1).
3.2. Metastases. Metastatic disease was present in 18/39
(46%) of PCS patients at the time of diagnosis. The distribution of metastases at the time of disease diagnosis is listed
in Table 1.
Twelve patients developed brain metastases, 4 of whom
had brain metastases at initial diagnosis. All presented with
neurologic symptoms. Median time from diagnosis of PCS
to diagnosis of brain metastases was 8.5 months (range 0–
75.8 months). Left-sided cardiac tumors were more commonly associated with brain metastases (9/12, p � 0.01)
compared to right-sided and pericardial tumors. The most
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Table 1: Patient demographics and disease characteristics.

Male
Female
Median tumor size in cm (range)
Median no. of total chemotherapy regimens
Primary tumor location
Right heart
Left heart
Pericardium
Histology
Angiosarcoma
High-grade undiﬀerentiated pleomorphic sarcoma
Leiomyosarcoma
Intimal sarcoma
Fibrosarcoma
Other
Metastatic disease present at diagnosis
Sites of metastases
Lung
Bone
Liver
Brain
Pancreas
Adrenal
Treatment
Surgery
R0
R1
R2
Unknown
Chemotherapy
Radiation to cardiac tumor
Median age in years (range)

No. of
patients (%)
13 (33)
26 (67)
6.5 (1.7–16)
2 (range 1–6)
16 (41)
18 (46)
5 (13)
14 (36)
10 (26)
5 (13)
3 (8)
2 (4)
5 (13)
18 (46)
10 (55)
7 (39)
5 (28)
4 (22)
1 (5)
1 (5)
25 (58)
3 (12)
9 (36)
11 (44)
2 (8)
28 (72)
3 (8)
41 (2–77)

common histological variant was UPS (n � 6). Other histological types included angiosarcoma (3), leiomyosarcoma
(2), and ﬁbrosarcoma (1). All patients with right-sided tumors and brain metastases at diagnosis (n � 3) also had lung
metastases. One patient had evidence of a right to left shunt
on echocardiogram as detected by a bubble study.
3.3. Surgery. Twenty-ﬁve patients (64%) underwent surgical
resection of their PCS. Eleven of the twenty-ﬁve (11/25, 44%)
patients had evidence of metastatic disease at diagnosis. An
R0 resection was obtained in only 3 patients (12%), all of
whom had left atrial tumors. Nine patients had R1 resections,
11 patients had R2 resections, and the surgical margin in 2
patients was unknown. Five patients with solitary brain
metastases underwent craniotomy as primary management
of their metastatic disease.
3.4. Radiation Therapy. In total, 11 patients (26%) received
radiation therapy. Three patients had radiation to the primary cardiac tumor, one to alleviate superior vena cava
syndrome and two to optimize clinical status prior to systemic chemotherapy. Eight patients received radiation
therapy to brain metastases (5 whole brain and 3 stereotactic
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FIGURE 1: Primary cardiac histology by tumor location.

radiotherapy). Four patients received radiation therapy after
resection of solitary brain metastases. Four patients received
radiation therapy alone for multifocal brain metastases. Two
of these patients received palliative radiation to symptomatic
lesions in the bone and lung.

diagnosis of brain metastases to death was 5.6 months (range
0–30 months).
Survival diﬀerences were not statistically signiﬁcant
based on the presence of metastatic disease at diagnosis,
tumor location, or tumor histology because, in part, of our
small sample size.

3.5. Systemic Therapy. Twenty-eight patients (72%) received
chemotherapy, with a median of 2 regimens (range 1–6).
Twenty-one patients (75%) who received chemotherapy had
resection of their primary tumor. Two patients received
neoadjuvant chemotherapy followed by resection, R0, and
R1. Figure 2 shows baseline (a) and posttreatment (b) imaging for a patient who received neoadjuvant chemotherapy
with good response, enabling subsequent resection.
Most patients received systemic therapy with palliative
intent. Seventeen patients (61%) received doxorubicin plus
ifosfamide (AI) as ﬁrst-line therapy with a mean of 5 cycles
(range 0.5–9). Ten patients received gemcitabine and
docetaxel (GT) as ﬁrst (n � 2) or second-line (n � 8) therapy.
Eight patients received 3 or more lines of therapy. Other
chemotherapy regimens frequently used in any line included
paclitaxel (n � 5), dacarbazine (n � 3), and ifosfamide
(n � 3).

4. Discussion

3.6. Survival. The median OS for patients who underwent
surgery was 14.0 months (range 1–79 months), compared to
8.2 months (range 0–33 months; p � 0.02) for patients who
did not (Figure 3(a)). Patients who received chemotherapy
lived longer compared to patients who did not with a median
OS of 14.0 months versus 2.4 months, respectively
(p � 0.0001, Figure 3(b)). Median OS for all patients was
12.1 months (range 0–79 months; Figure 3(c)). Three patients were alive at the time of data assessment in October
2017, one diagnosed in 2015 and two diagnosed in 2016
(median follow-up time of 19 months). Median time from

We present our single-institution experience with primary
cardiac sarcoma with several notable ﬁndings: a high incidence of metastatic disease to the brain as compared to
sarcomas originating in other locations, pattern of metastatic spread associated with location of sarcoma origin
within the heart, predilection of certain histologies to
originate in the right versus left heart, and association of
multimodality therapy with improved patient survival despite the lack of a standardized treatment approach.
We found brain metastases occurred quickly and frequently in our PCS patients. Thirty-one percent (12/39) of
our PCS patients developed brain metastases, compared to
1–8% in noncardiac sarcomas [2–7]. This is close to the
estimated 10–30% prevalence of brain metastases in all
cancer patients [8]. The median length of time from diagnosis to the development of brain metastases has been
reported to be about 27 months in other soft tissue sarcomas
[2, 3, 6, 9, 10]. In our patient cohort, however, the median
time from diagnosis of PCS to brain metastasis was
8.5 months (range 0.3–75.8 months). This may be secondary
to the intracardiac location of primary tumors, potentially
providing a more direct conduit from tumor to the brain via
the cardiac outﬂow tract, particularly in left-sided tumors.
There are case reports of brain metastases developing in
patients with angiosarcoma, HGPUS, and leiomyosarcoma
[3–5, 7, 9–16]. In our series, the most common histology to
metastasize to the brain was high-grade undiﬀerentiated
pleomorphic sarcoma (n � 6).
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Figure 2: Baseline cardiac MRI shows a large, heterogeneous mass in the pericardial space with a large eﬀusion and compression of the left
atrium (a). Neoadjuvant chemotherapy with doxorubicin/ifosfamide ×12 cycles and gemcitabine/docetaxel ×6 cycles resulted in near
complete response (b).
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Figure 3: Overall Survival of cardiac sarcoma patients (n � 39). Overall survival was signiﬁcantly improved with surgical resection of PCS
(a) and chemotherapy administration (b). For all patients (c), median overall survival was 12.1 months (range 0–79 months). The dashed
curve represents surgery or chemotherapy and solid curve no intervention.

The prevalence of brain metastases in sarcoma is increasing due to prolonged survival from multimodal therapies that have poor CNS penetration [17, 18]. In our

patients who lived longer than 12 months (22 pts), brain
metastases eventually developed in 9 (41%). Median OS for
our patients with brain metastases was 13.6 months, with a
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post-brain metastases median survival of 5.6 months. This is
signiﬁcantly shorter than reports of brain metastases in
sarcomas of all primary sites, which have a median of
13.9 months from diagnosis to development of brain metastases and overall and postmetastasis survival of 15 and
9.2 months, respectively [3, 5].
The management of brain metastases is largely dependent on the number of lesions and patient performance
status. Surgical intervention is considered with solitary
metastases, while radiation therapy is preferred for multifocal disease or in patients with marginal performance
status. Metastasectomy of brain metastases is reported to
result in increased post-brain metastases survival to about
9 months, compared with 2.7 months for those who did not
receive surgical intervention [3]. In our cohort, one patient
underwent metastasectomy alone with a post-brain metastases survival of 12 months. In our cohort, 4 patients received radiation therapy for brain metastases with a median
post-brain metastases survival of 8 months. Four patients
underwent surgical resection followed by radiation with a
post-brain metastases survival of 5.5 months. Since most
patients had received chemotherapy by the time they develop brain metastases, the role of chemotherapy in brain
metastases remain unclear [5, 16].
Surgical resection is the preferred management for
localized sarcomas. As compared to other sarcomas, PCS
patients are more likely to have advanced stage or inoperable primary tumor at presentation. Barriers to
complete resection include anatomic location and declining performance status due to tumor at presentation.
Given the diﬃculty in achieving complete resection with
cardiac tumors, autotransplantation has been explored to
allow for complete resection and optimal reconstruction.
Ramlawi et al. reported on their institutional experience
with cardiac transplant in 34 patients with left-sided cardiac tumors [19]. In their series, 26 patients had primary
cardiac sarcomas. In those with malignant tumors, 1- and
2-year survival was 46% and 28%, respectively. While the
authors conclude cardiac autotransplantation to be feasible
and safe for complex left-sided tumors, this should only be
considered in certain individuals and performed at experienced specialty centers.
Nearly 50% of our patients had evidence of metastatic
disease at time of presentation, which is higher than the
reported 20–30% in several case series [20–23]. In our patient cohort, metastatic disease at presentation did not
impact survival compared with those with localized disease
(14 months versus 10 months, p � 0.12, respectively), while
surgical resection did (p � 0.02), highlighting the importance of local disease control. This survival beneﬁt of resection has been noted in other reports of PCS and is
independent of the presence of metastatic disease [24]. This
may be due to the preservation of cardiac function as heart
failure has been described as the most common cause of
death of PCS patients [25]. Furthermore, improved cardiac
function ultimately aids in ability to administer systemic
therapy, speciﬁcally an anthracycline.
Surgery alone, however, is not enough to prevent primary tumor recurrence or distant metastases. Most patients
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who undergo complete (R0) resections without metastatic
disease will relapse, highlighting the need for systemic
therapy [22, 26]. Although multimodal therapy for PCS
patients is associated with improved survival [20, 21, 26],
the speciﬁc role of radiation and chemotherapy alone or in
combination in PCS has yet to be deﬁned. A univariate
analysis by Isambert et al. found that chemotherapy oﬀered
a survival advantage only in patients who did not undergo
primary cardiac tumor resection [24]. Abu Saleh et al.
reviewed the utility of neoadjuvant chemotherapy in the
management of right-sided cardiac tumors in 44 patients
[27]. In their cohort, 73% of patients received neoadjuvant
chemotherapy consisting of doxorubicin and ifosfamide.
There was a signiﬁcant improvement in median overall
survival in patients who achieved a complete (R0) versus R1
resection, 53.5 months and 9.5 months, and those who
received neoadjuvant chemotherapy versus primary surgery, 20 versus 9.5 months, respectively. The authors
conclude that neoadjuvant chemotherapy improves the
ability to achieve complete resection and thus translates
into improved survival. However, the ability to deliver
neoadjuvant chemotherapy relies on accurate preresection
diagnosis. Given the rarity of these tumors and clear
beneﬁts to multimodality therapies, it is imperative to
employ a multidisciplinary team approach. The creation of
a multispecialty, multi-institution cardiac tumor board in
which our institution participates enhances the ability for
cross-discipline discussions to optimally manage these
challenging tumors.
In our patient cohort, those who received chemotherapy alone and those who underwent surgical resection
and received systemic chemotherapy had a survival advantage (p � 0.039) compared to those who did not receive
chemotherapy. Given the retrospective nature of this
study, it is important to note that patients who receive
chemotherapy generally have better performance status
and organ function, which likely impacted the survival
advantage noted with chemotherapy. Local disease control, resulting in improved cardiac function, likely results
in better performance status and ability to tolerate aggressive therapies.

5. Conclusions
Primary cardiac sarcomas are rare, confer increased risk of
brain metastases, are associated with shorter survival duration, and have a higher disease-speciﬁc mortality compared to soft tissue sarcomas arising in extracardiac sites.
Increased mortality may be due to the diﬃculty with
complete resection and high disease and symptom burden at
presentation, making aggressive multimodal therapy diﬃcult. Multidisciplinary care incorporating surgery, radiation,
and systemic therapy when appropriate constitutes ideal
management. Based on our ﬁndings, we recommend brain
imaging at the time of primary cardiac sarcoma diagnosis
given the incidence of brain metastases. Furthermore, our
results suggest a role for aggressive multimodal therapy
including resection and systemic therapy, even in the
metastatic setting, to improve outcomes.
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